# Surgery Partners Inc. (SGRY) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Health Care Equipment & Supplies. Price $14.26, market value $1.9 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Surgery Partners Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **PEG: 0.42**. A PEG of 0.42 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 0.6×**. Each dollar of revenue is priced at 0.6×, a low multiple typical of thin-margin businesses or out-of-favour stocks.
- **Price / book: 1.1×**. The shares trade at 1.1× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 9.6×**. Enterprise value is 9.6× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: 10.0%** (5-yr avg 5.3%). Free cash flow equals 10.0% of the market value, above its five-year average of 5.3%, so the shares are cheaper on cash than they have usually been. Above 5% is generally attractive.

## Profitability
- **Operating margin: 11.4%**. 11.4% of revenue is left after running the business.
- **Net margin: -2.4%**. The company reported a net loss over the last twelve months.
- **Return on equity: -4.5%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: 5.8%**. Return on all capital, debt included, is 5.8%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -1.1%**. Each dollar of assets produces -1.1% of profit.

## Growth
- **Revenue growth (1 yr): 6.2%** (3-yr 9.2%/yr, 5-yr 12.2%/yr). Revenue grew 6.2% over the last year, against 12.2% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 54.1%**. Earnings per share rose 54.1%, faster than revenue, so margins expanded or the share count shrank.
- **Free-cash-flow growth (3 yr): 35.7%/yr**. Free cash flow has compounded at 35.7% a year over three years.

## Financial health
- **Debt to equity: 2.18**. Debt is 2.18 times equity, a leveraged balance sheet that needs steady cash flow to service.
- **Net debt / EBITDA: 6.2×**. It would take 6.2 years of operating earnings to repay net borrowings, above the 3× level most lenders treat as comfortable.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Surgery Partners Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (11 analysts). 11 analysts cover Surgery Partners Inc.; the consensus is buy, with an average price target of $18.73 (+31% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -36.2%** (YTD -7.7%, 3-mo 4.0%). The shares are down 36.2% over twelve months including dividends.
- **From 52-week high: -39.2%** (25.0% above the low). Trading 39% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 47**. An RSI of 47 is neutral.
- **Beta (1 yr): 0.71** (volatility 48%). Beta of 0.71 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=SGRY · Page: https://foliofundamentals.com/stocks/sgry

Not investment advice.